Skip to main content
SpringerLink
Log in

3-monthly paliperidone: better outcomes, lower cost

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by Janssen.

Reference

  • Arteaga C, et al. Assessing the Cost-Effectiveness of Three-Monthly Paliperidone Palmitate Versus its Prior Monthly Formulation for the Management of Schizophrenia in the Uk Setting. 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PMH34, 19 May 2018. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/81660?pdfid=54619

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

3-monthly paliperidone: better outcomes, lower cost. PharmacoEcon Outcomes News 805, 4 (2018). https://doi.org/10.1007/s40274-018-5006-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5006-z

Search

Navigation